Announcements Trials
Browse Landscape

Phase

Phase 1 3

Status

Active not recruiting 10Terminated 7Recruiting 7Withdrawn 3Not yet recruiting 3Completed 3Unknown 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1Gastrointestinal 1

Conditions

Pancreatic Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Healthy Adults 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Advanced Solid Tumor 1

Interventions

Cyclophosphamide 1488Cisplatin 1410Paclitaxel 1316Radiotherapy 1259Carboplatin 1247Gemcitabine 1214Docetaxel 1110Bevacizumab 1029Fluorouracil 894Doxorubicin 786Dexamethasone 746Rituximab 719Capecitabine 716Oxaliplatin 700pembrolizumab 673Etoposide 673Irinotecan 634Filgrastim 621Cytarabine 584Leucovorin 578Nivolumab 557Vincristine 510Prednisone 474Cetuximab 464Bortezomib 457Erlotinib Hydrochloride 456Trastuzumab 448Methotrexate 437Lenalidomide 426Pemetrexed 419

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × Interventional × adagrasib × Clear all
NCT04330664 2025-04-04

Adagrasib in Combination With TNO155 in Patients With Cancer (KRYSTAL 2)

Mirati Therapeutics Inc.

Phase 1 Completed
86 enrolled
GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Neoplasm Metastasis, Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

NCT05178888 2025-02-11

Adagrasib in Combination With Palbociclib in Patients With Advanced Solid Tumors (KRYSTAL-16)

Mirati Therapeutics Inc.

Phase 1 Completed
11 enrolled
Other solid neoplasm

Advanced Solid Tumor

NCT05924152 2024-03-13

A PK Study to Assess the Drug-drug Interaction of a BCRP Inhibitor on Adagrasib

Mirati Therapeutics Inc.

Phase 1 Completed
16 enrolled

Healthy Adults

Data powered by HemOnc (CC BY 4.0) Colophon âš¡